Patient received 3 doses of the vaccine, on 3/12/21, 4/9/21, and 11/26/21; COVID-19 infection; sore throat; post nasal drip; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (sore throat), UPPER-AIRWAY COUGH SYNDROME (post nasal drip), COVID-19 (COVID-19 infection) and MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received 3 doses of the vaccine, on 3/12/21, 4/9/21, and 11/26/21) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     No Medical History information was reported.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 26-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On 04-Jun-2022, the patient experienced OROPHARYNGEAL PAIN (sore throat) and UPPER-AIRWAY COUGH SYNDROME (post nasal drip). On 06-Jun-2022, the patient experienced COVID-19 (COVID-19 infection). On an unknown date, the patient experienced MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received 3 doses of the vaccine, on 3/12/21, 4/9/21, and 11/26/21). At the time of the report, OROPHARYNGEAL PAIN (sore throat), UPPER-AIRWAY COUGH SYNDROME (post nasal drip) and COVID-19 (COVID-19 infection) outcome was unknown and MATERNAL EXPOSURE BEFORE PREGNANCY (Patient received 3 doses of the vaccine, on 3/12/21, 4/9/21, and 11/26/21) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Jun-2022, SARS-CoV-2 test: negative Negative home Covid test.. On 05-Jun-2022, SARS-CoV-2 test: negative Negative. On 06-Jun-2022, SARS-CoV-2 test: positive Positive. Patient received a positive test result on a home Covid test.         No concomitant and treatment medications were reported.  Patient was 21 weeks and 3 days pregnant with a singleton child.  Company Comment: This is a spontaneous case concerning a 39-year-old female patient who is currently pregnant at 21 weeks and 3 days at the time of report, with no reported medical history, and who experienced the unexpected, non-serious, adverse event of special interest, COVID-19. The event occurred approximately 7 months after receiving the third dose of mRNA-1273 Vaccine. This is also a case of Maternal Exposure Before Pregnancy, Last menstrual period and estimated date of delivery were not provided. No further information on risk factors, co morbidities, clinical course and management of the events was available in the report. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Sender's Comments: This is a spontaneous case concerning a 39-year-old female patient who is currently pregnant at 21 weeks and 3 days at the time of report, with no reported medical history, and who experienced the unexpected, non-serious, adverse event of special interest, COVID-19. The event occurred approximately 7 months after receiving the third dose of mRNA-1273 Vaccine. This is also a case of Maternal Exposure Before Pregnancy, Last menstrual period and estimated date of delivery were not provided. No further information on risk factors, co morbidities, clinical course and management of the events was available in the report. It was reported that the outcome of the event was unknown. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.